Comparative Pharmacology
Head-to-head clinical analysis: NAPROSYN versus OXAPROZIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROSYN versus OXAPROZIN.
NAPROSYN vs OXAPROZIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in decreased inflammation, pain, and fever.
Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which results in anti-inflammatory, analgesic, and antipyretic effects.
250-500 mg orally twice daily; maximum 1500 mg/day. For extended-release: 750-1000 mg orally once daily.
600-1200 mg orally once daily; maximum 1800 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12-17 hours. This long half-life allows twice-daily dosing, but may lead to drug accumulation in elderly or renally impaired patients.
Clinical Note
moderateOxaprozin + Gatifloxacin
"Oxaprozin may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateOxaprozin + Rosoxacin
"Oxaprozin may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateOxaprozin + Levofloxacin
"Oxaprozin may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateOxaprozin + Trovafloxacin
"Oxaprozin may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is approximately 50–60 hours in healthy adults; clinical context: once-daily dosing achieves steady-state in 7–10 days.
Renal excretion of conjugated metabolites accounts for approximately 95% of a dose, with 1-2% as unchanged naproxen. Fecal excretion is minimal (<5%).
Primarily hepatic metabolism (glucuronidation and hydroxylation) with renal excretion of metabolites; less than 1% excreted unchanged in urine; fecal elimination accounts for ~20%.
Category C
Category D/X
NSAID
NSAID